{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:19Z","timestamp":1759334239098,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.lungcan.2023.107193","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T01:43:17Z","timestamp":1681090997000},"page":"107193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma"],"prefix":"10.1016","volume":"179","author":[{"given":"Koki","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2023.107193_b0005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicenter, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107193_b0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic Epithelial Tumor Working Group, Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2023.107193_b0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107193_b0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107193_b0025","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/curroncol29050266","article-title":"Identification of CT values that could be predictive of necrosis (N-CTav) in hepatocellular carcinoma after lenvatinib treatment","volume":"29","author":"Chuma","year":"2022","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107193_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-017-1321-6","article-title":"\u201cPsuedo-progression\u201d in advanced thyroid cancer in response to kinase inhibitor therapy","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"23","key":"10.1016\/j.lungcan.2023.107193_b0035","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107193_b0040","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.jtho.2018.05.008","article-title":"CD103+CD8+ Lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC","volume":"13","author":"Pedro","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107193_b0045","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107193_b0050","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.21873\/anticanres.13802","article-title":"Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo","volume":"39","author":"Ogasawara","year":"2019","journal-title":"Anticancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:09Z","timestamp":1759237509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223007316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":10,"alternative-id":["S0169500223007316"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107193","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107193"}}